Skip to main content
Fig. 6 | Clinical Epigenetics

Fig. 6

From: Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype

Fig. 6

Cell viability of U-87 and GL1 untreated (ctr) and treated with 25 μM MC4040 or MC4041 or tazemetostat, and with 100 μM temozolomide as single or combined treatments expressed as percentage of alive cells. Treatments were performed at 72 h (a, dark grey), 96 h (b, light grey) and 120 h (c, white). *p < 0.05 and **p < 0.01 for the comparison between single treatments and untreated cells. #indicates p < 0.05 for the comparison between each combined treatment and each single treatment with MC4040 and MC4041. §p < 0.05 for the comparison between each combined treatment and the single treatment with temozolomide

Back to article page